MEK inhibitor for gastric cancer with MEK1 gene mutations

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• The prognosis for unresectable advanced or recurrent gastric cancer is poor.
• There is a need to identify oncogenes driving cancer growth, similar to epidermal growth factor receptor.
• Understanding MEK pathway alterations is crucial for developing targeted therapies.

Purpose of the Study:

• To evaluate the sensitivity of gastric cancer cell lines to MEK inhibitors.
• To identify genetic alterations associated with MEK inhibitor sensitivity.
• To investigate the functional role of MEK1 mutations in gastric cancer progression and therapeutic response.

Main Methods:

• In vitro sensitivity testing of gastric cancer cell lines to MEK inhibitors (GSK1120212, PD0325901).
• Sequence analysis to identify mutations in MEK1, KRAS, and other relevant genes.
• Functional studies using MEK1 expression vectors to assess phosphorylation of ERK1/2 and tumorigenicity.
• In vivo studies to evaluate the efficacy of MEK inhibitors on tumor growth.
• Analysis of MEK1 mutations in clinical gastric cancer samples.

Main Results:

• Three poorly differentiated gastric cancer cell lines exhibited hypersensitivity to MEK inhibitors.
• Identified a novel MEK1 mutation in one cell line, and previously reported KRAS and MEK1 mutations in two others.
• MEK1 mutations were shown to induce ERK1/2 phosphorylation and enhance tumorigenicity.
• MEK inhibitors effectively reduced ERK1/2 phosphorylation, induced apoptosis, and inhibited tumor growth in vitro and in vivo.
• A MEK1 mutation was found in one of 46 clinical gastric cancer samples, associated with poorly differentiated histology.

Conclusions:

• Gastric cancer cells can be addicted to active MEK1 mutations for proliferation.
• Oncogenic MEK1 mutations represent a potential therapeutic target in gastric cancer.
• MEK inhibitors show promise for targeted therapy in gastric cancer patients with specific MEK1 mutations.